REQUIRED PRICE DISCLOSURES

COLORADO

Information for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131.

LEQEMBI® (lecanemab-irmb)
LENVIMA® (lenvatinib)
DAYVIGO® (lemborexant), CIV

VERMONT – SHORT FORMS

Information for Vermont Prescribers of Prescription Drugs Provided Pursuant to Vermont Law 33 V.S.A § 2005a.

LENVIMA® (lenvatinib)
DAYVIGO® (lemborexant), CIV

CONNECTICUT

Information for Connecticut Pharmacists and Prescribers of Prescription Drugs Provided Pursuant to Connecticut House Bill 6669.

LEQEMBI® (lecanemab-irmb)
LENVIMA® (lenvatinib)

WHO WE ARE

hhc Mission
Our Locations
Corporate Responsibility
Leadership
Awards and Recognitions
Our History
Collaboration

OUR SCIENCE

Global Pipeline
Disease Areas
Clinical Trials
G2D2

OUR MEDICINES

Our Products
Manufacturing
Eisai Medical Information
Pharmacy Trade Relations

OUR PATIENT FOCUS

Community Involvement
Magnolia Patient Support
Eisai USA Foundation
Eisai Grants Programs

CAREERS AT EISAI

Search Job Openings
Career Areas
Life at Eisai
Career Growth & Development
Compensation &
Benefits
What Matters to Us

MEDIA CENTER CONTACT US VIEW CLINICAL TRIALS

Site Map Cookie Preferences US Privacy Policy Your Choices and Rights California Privacy Supplement

Consumer Health Data Privacy Supplement Legal Notices & Industry Practices EU/UK Privacy Policy

Eisai Co. Ltd.

Eisai CA

Eisai EU

This is the website of Eisai Inc., a US company. This site is intended for US residents only. The health information contained
herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All
decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.

YOU’RE ABOUT TO LEAVE US.EISAI.COM

By clicking on the CONTINUE button you will be leaving the Eisai Inc. U.S. website. Eisai assumes no responsibility for, and exercises no control over, the accuracy or information on this external website.